Regional media highlights UC pancreatic cancer vaccine trial
Regional media highlighted the University of Cincinnati Cancer Center being the first site in the Midwest enrolling patients in a new Phase 2 clinical trial testing a vaccine to treat pancreatic cancer.
Davendra Sohal, MD, site principal investigator, said this trial builds on the same mRNA technology that was used to develop vaccines for COVID-19.
"In addition to the standard surgery and chemotherapy, they also get this very personalized vaccine created using their own tumor profile,” Sohal, associate director for clinical research at the Cancer Center and professor of internal medicine in UC’s College of Medicine, told Local 12.
The vaccine is developed in about four to six weeks while patients are recovering from surgery, and patients are then given six weekly injections of the vaccine. Following six months of standard chemotherapy, patients then receive six more vaccine injections as boosters.
In the Phase 1 trial, Sohal said eight out of 32 patients were completely cured of their cancer.
Watch or read the Local 12 story.
Read the Becker's Hospital Review story.
Read the WDRB Louisville story.
For more information on the trial, please call 513-584-7698 or email cancer@uchealth.com.
Featured photo at top of a vaccine being administered. Photo/National Cancer Institute/Unsplash.
Related Stories
UC biologist talks about 'pearmageddon'
March 16, 2026
WLWT talks to UC biologist and Department Head Theresa Culley about invasive, nonnative Callery pear trees that are spreading across Ohio forests after they were introduced by landscapers more than 50 years ago.
Local media highlight completion of Blood Cancer Healing Center fourth and fifth floors
March 16, 2026
Local media including WLWT and the Cincinnati Business Courier highlighted the opening of research laboratories and the UC Osher Wellness Suite and Learning Kitchen at the University of Cincinnati Cancer Center’s Blood Cancer Healing Center.
Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy
March 16, 2026
Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.